TORONTO, Ontario — July 16, 2026 — Leads & Copy — TerrAscend Corp., a prominent North American cannabis operator, announced today its intention to host a conference call on Thursday, August 6, 2026, at 5:00 p.m. Eastern Time. The purpose of the call is to discuss the financial results for the company’s second quarter, which concluded on June 30, 2026. TerrAscend will release its second quarter financial results for 2026 on the same day, following the market’s close.
Participants in the conference call can access the discussion via a webcast at https://app.webinar.net/KdQDYQEYArL. The dial-in number for the call is 1-888-510-2154. A replay of the call will be available until 12:00 midnight Eastern Time on Thursday, August 20, 2026, accessible by dialing 1-289-819-1450 or 1-888-660-6345, using the entry code 58705#.
TerrAscend Corp. is recognized as a leading cannabis company with operations spanning the North American sector. The company’s interests include operations in Pennsylvania, New Jersey, Maryland, Ohio, and California through its subsidiary TerrAscend Growth Corp., as well as retail operations in Canada. TerrAscend manages a portfolio of dispensary retail locations, including The Apothecarium, alongside large-scale cultivation, processing, and manufacturing facilities in its primary markets.
The company’s cultivation and manufacturing processes are designed to produce consistent, high-quality cannabis products, catering to both the medical and legal adult-use markets. TerrAscend holds ownership or licenses for several complementary businesses and brands, such as The Apothecarium, Cookies, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. Further details about the company can be found at www.terrascend.com.
The company also provided a caution regarding its cannabis operations in the United States. Investors are advised of the significant legal restrictions and regulations governing the cannabis industry in the U.S. While the U.S. Department of Justice issued a final rule on April 23, 2026, rescheduling marijuana in FDA-approved drug products and in state-licensed medical marijuana programs from Schedule I to Schedule III of the Controlled Substances Act, any form of marijuana not falling under these categories remains a Schedule I controlled substance. Handling such material carries the risk of regulatory controls and sanctions applicable to Schedule I substances.
Financial transactions associated with cannabis-related business activities in the United States could potentially lead to prosecution under U.S. federal money laundering legislation. Although federal enforcement in the U.S. has generally trended towards non-enforcement for entities compliant with state medical or adult-use cannabis programs, strict adherence to state laws does not exempt the Company from liability under U.S. federal law nor serve as a defense against any federal proceedings. The enforcement of federal laws in the United States poses a significant risk to TerrAscend’s business, and any related proceedings could negatively impact its operations and financial performance.
Source: TerrAscend Corp.
